Matthieu
Schmit
ab,
Md. Mahadhi
Hasan‡
c,
Yashad
Dongol
c,
Fernanda C.
Cardoso
c,
Michael J.
Kuiper
d,
Richard J.
Lewis
c,
Peter J.
Duggan
*be and
Kellie L.
Tuck
*a
aSchool of Chemistry, Monash University, Victoria 3800, Australia. E-mail: Kellie.Tuck@monash.edu
bCSIRO Manufacturing, Research Way, Clayton, Victoria 3168, Australia. E-mail: Peter.Duggan@csiro.au
cInstitute for Molecular Bioscience, The University of Queensland, St. Lucia, QLD 4072, Australia
dCSIRO Data 61, Clunies Ross Street, Acton ACT 2601, Australia
eCollege of Science and Engineering, Flinders University, Adelaide, South Australia 5042, Australia
First published on 12th June 2024
Neuropathic pain is a type of chronic pain, usually caused by nerve damage, that responds poorly to traditional pain therapies. The N-type calcium channel (CaV2.2) is a well-validated pharmacological target to treat this condition. In order to further improve the inhibition of the N-type calcium channel relative to previously described inhibitors, and also address their problematic instability in blood plasma, the development of N-sulfonylphenoxazines as new calcium channel inhibitors was pursued. A series of N-sulfonylphenoxazines bearing ammonium side chains were synthesised and tested for their ability to inhibit both CaV2.2 and CaV3.2 (T-type) neuronal ion channels. Compounds with low micromolar activity in CaV2.2 were identified, equivalent to the most effective reported for this class of bioactive, and calculations based on their physical and chemical characteristics suggest that the best performing compounds have a high likelihood of being able to penetrate the blood–brain barrier. Representative N-sulfonylphenoxazines were tested for their stability in rat plasma and were found to be much more resilient than the previously reported N-acyl analogues. These compounds were also found to be relatively stable in an in vitro liver microsome metabolism model, the first time that this has been investigated for this class of compound. Finally, molecular modelling of the CaV2.2 channel was used to gain an understanding of the mode of action of these inhibitors at a molecular level. They appear to bind in a part of the channel, in and above its selectivity filter, in a way that hinders its ability to undergo the conformational changes required to open and allow calcium ions to pass through.
Neuropathic pain does not respond well to traditional pain management therapies that employ non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin or ibuprofen; in about half of the cases, only 30 to 50% pain relief is achieved. Safe and effective therapies are lacking. First line treatments typically rely on antidepressants or anticonvulsant drugs used outside of their initial indication,5 while in more severe cases opioids are employed.4,6,7 In recent decades, voltage-gated calcium channels (VGCC), in particular the N-type (CaV2.2) and T-type (CaV3.1, 3.2 and 3.3) subtypes, have emerged as promising and valid targets and have become a major focus of research into the treatment of neuropathic pain.8,9 These channels are expressed by cells involved in the transmission of action potentials characteristic of neuropathic pain; thus it is hypothesised that these inhibitors owe their pain blocking effect to shutting down such signals.10 While there are many new inhibitors undergoing clinical trials, there are currently only three drugs targeting VGCCs approved by the United States Food and Drug Administration for the treatment of neuropathic pain – gabapentin, pregabalin and ziconotide. Gabapentin and pregabalin are small amino acids, initially designed as gamma-amino butyrate (GABA) analogues for the treatment of epilepsy, and have limited effectiveness. Ziconotide, on the other hand, is a synthetic version of the peptide ω-conotoxin MVIIA found in the venom of the marine snail Conus magus and is a selective inhibitor of CaV2.2 channels. Treatment with ziconotide requires that it is injected intrathecally into the spinal fluid of the patient. While it was shown to deliver superior pain relief to that provided by morphine, with no addictive symptoms, the severe side effects and the invasive mode of administration makes ziconotide a less than ideal drug.8
Two molecules currently undergoing clinical trials are PP353 (Phase 1b, Persica Pharmaceuticals), an antibiotic formulation for treating chronic lower back pain,11 and STA363 (Phase 2b, Stayble Therapeutics), aimed at treating pain from herniated discs.12 The structures of both molecules are currently not in the public domain.
The present study stemmed from a series of iterations beginning with mimics of ω-conotoxin GVIA and proceeding towards smaller, open chain aromatic compounds,13 and then more constrained analogues, from which the acylphenoxazines 1a–1d (Fig. 1) were obtained.14 These compounds showed promising channel-blocking activity relative to positive controls, and in the case of 1b–1d, favourable central nervous system multiparameter optimisation (CNS MPO)15,16 scores. However, 1d in particular was found to be quite unstable in rat plasma, readily undergoing diacylation, and hence making these acyl derivatives unsuitable for further development. In a recently published study, a similar instability in open chain phenoxyanilides was overcome through the substitution of the amide with a more robust sulfonamide link. Interestingly, this was also associated with a marked improvement in the functional inhibition of the target CaV2.2 ion channel.17 In the current work, the acyl link in the acylphenoxazines 1b–1d was substituted for a sulfonyl moiety in a similar way. In addition, the importance of the nature of the side chain on channel blocking activity was further explored with an expanded set of terminal amines, and for the first time, an in silico model based on a recently reported CaV2.2 Cryo-EM structure18 was used to rationalise the observed results obtained with this class of compound. Finally, the stability of significant compounds in in vitro plasma and liver microsome assays was also assessed.
![]() | ||
Fig. 1 Chemical structures and ion channel inhibition activity, determined by calcium influx fluorescence imaging assays, of previously reported14 acylphenoxazines 1a–1d. |
A series of sulfonylphenoxazines was also prepared where the oxygen link to the sidechain was replaced with a nitrogen, as described in Scheme 2. Sulfonylation of phenoxazine was again readily achieved in pyridine, this time with p-nitrosulfonyl chloride (5), to yield the nitro compound 6. Hydrogenation gave the aniline 7, which was acylated with 3-chloropropionyl chloride to give the amide 8. Borane reduction yielded the substituted aniline 9, which was converted to a series of diamines (10a–10f) in a one-pot Finkelstein reaction followed by alkylation of the appropriate amine. The N-methylated aniline 12 was prepared via a reductive amination to give 11, which was used to alkylate dimethylamine. Reductive amination of the aniline 7 with Boc-protected piperidone gave the Boc-protected piperidine 13, which was deprotected the give the free amine 14. All final compounds (10a–10f, 12 and 14) were purified by RP-HPLC and obtained as di-TFA salts.
A methoxy analogue of the amines 4a–4f was also prepared in order to gauge the importance of the terminal amine on CaV2.2 binding affinity. The methoxy compound (15) was prepared from 3via a one-pot Finkelstein reaction followed a substitution reaction with methoxide (Scheme 3). Under the conditions of the reaction 15 was produced as a 1:
1 mixture with the corresponding allyl ether, which resulted from an elimination reaction, with the two products readily separated using a combination of normal and reversed phase chromatography.
![]() | ||
Fig. 2 Chemical structure and ion channel inhibition activity, determined by calcium influx fluorescence imaging assays, of recently reported17 open chain sulfonylamide 16. |
Compound | IC50 (μM) | SEM | 95% CI (μM) |
---|---|---|---|
a From ref. 14. b From ref 17. | |||
Cilnidipine | 26 | 4 | 9–43 |
1a | 404 | 39 | 250–650 |
1b | 44 | 2 | 35–55 |
1c | 36 | 2 | 28–44 |
1d | 129 | 6 | 103–161 |
4a | 4.6 | 0.6 | 3.8–5.3 |
4b | 4.3 | 0.6 | 3.6–5.0 |
4c | 8.0 | 1.0 | 6.7–9.3 |
4d | 48.7 | 3.2 | 44.4–53.0 |
4e | 7.6 | 1.1 | 6.1–9.1 |
4f | 29.0 | 2.5 | 25.7–32.3 |
10a | 10.9 | 1.6 | 7.4–14.4 |
10b | 9.1 | 1.0 | 6.5–11.6 |
10c | 4.4 | 0.5 | 3.2–5.6 |
10d | 13.7 | 1.7 | 8.3–19.1 |
10e | 15.2 | 2.1 | 10.4–20.0 |
10f | 20.8 | 1.6 | 15.4–26.2 |
12 | 18.7 | 3.6 | 13.8–23.6 |
14 | 19.9 | 2.4 | 16.6–23.2 |
15 | 172 | 21 | 144–199 |
16 | 5.5 | 0.8 | 4.9-6.1 |
![]() | ||
Fig. 3 Side view of the α1 subunit of the CaV2.2 Cryo-EM structure.18 Domains I to IV are represented in blue, red, green and yellow respectively. The approximate boundaries of docking sites 1, 2 and 3 are designated in light blue, purple and orange rectangles respectively. |
A rigid docking study was undertaken in an attempt to identify the most likely binding sites for the N-sulfonylphenoxazines in the CaV2.2 channel and to understand better the origins of the observed trends in inhibition values. The cryo-EM structure of the channel, determined by Gao et al.,18 was imported into Schrödinger Maestro®20 and the compounds prepared in this study were then rigidly docked into the three sites designated in Fig. 3. There was no observed correlation between the docking scores obtained and experimentally determined inhibition values, but the docking scores obtained for sites 2 and 3 were consistently more favourable than those for site 1.
Images of the results obtained with the dimethylamine (4b) docked into the three binding sites are shown in Fig. 4 and S1.† Consistent with the results of the modelling studies of the binding of tricyclic antidepressants (TCAs) to CaV2.2,5 all three poses show salt-bridge and hydrogen bond interactions between the ammonium tail and the glutamate residues of the selectivity filter. Similar interactions are not possible with the methoxy analogue (15), which experimentally was found to be a two orders of magnitude weaker inhibitor than its amine analogue (4a), emphasising that the ability of the ammonium tails of these compounds to bind to the CaV2.2 selectivity filter appears to be a critical feature of their inhibition effect. The phenoxazine head group of the compounds in this study was found to be coordinated to S6 segments, which together form the internal gate of the channel. It has previously been hypothesised that close coordination of small molecule inhibitors with the S6 segments of the protein structure prevents these segments from efficiently moving away from each other when the channel opens, as having the drug desorb would be thermodynamically unfavourable.5,19 This may also explain why MONIRO-1, an earlier analogue of the compounds studied here, was found to be a state-dependent inhibitor of CaV2.2 with a higher affinity for the inactivated state,21 in which the internal gate is closed. It is not clear why MONIRO-1 would be state-dependent if it bound to CaV2.2 in docking site 1, as the P2 segments are not known to undergo conformational shifts during channel activation, unlike the S6 segments.22,23 Coordination of the phenoxazine head group of the compounds in this study to S6 segments may also explain the relatively low but significant residual activity of 15 (IC50: 172 μM). While this compound lacks the ammonium tail group to disrupt the selectivity filter, it would be able interact with the S6 segments in the same way as 4b and the other phenoxazine analogues appear to do. Therefore, most factors seem to indicate that docking sites 2 and 3 are more likely than docking site 1 to be the actual binding site of the phenoxazine compounds developed.
![]() | ||
Fig. 4 Ligand interaction diagrams of protonated 4b in docking site 1 (A), docking site 2 (B), and docking site 3 (C). |
The substitution of the acyl link to the phenoxazine unit with a sulfonyl attachment resulted in an order of magnitude improvement in potency (compare IC50s for 1b–1d with 4b, 4c and 4f) and when 4b was docked into binding site 2 an interaction with the sulfonamide oxygens was observed. In this case Ser1362 was seen to form a hydrogen bond with one of the sulfonamide oxygens. While this was not evident with all of the sulfonylphenoxazines examined, when docked into binding site 2 (Fig. 5), the sulfonamide group was consistently found to be within 3 Å of hydrogen donor residues – either Ser1362, Thr1363 and/or Ser1696. No such association was found when the phenoxazines were docked into site 3. Based on these findings, it appears that the binding of the sulfonylphenoxazines into site 2 is primarily responsible for their inhibition of CaV2.2 ion channels. Qualitatively, docking site 1 is a larger pocket, rich in polar and charged residues, and in contact with water. It appears less suited for binding lipophilic molecules like the sulfonylphenoxazines, compared to docking site 2 and 3, which are located in the transmembrane and are rich with lipophilic residues.
The series in which the ether linkage was replaced with an amine (10a–10f, 12 and 14) was prepared in the hope that additional hydrogen bond and/or salt bridge associations would improve the affinity to the CaV2.2 channel. In most cases, this change had a limited or even slightly detrimental effect on channel affinities, with only the imidazole 10d showing a marked improvement. Consistent with this, no interactions with either the aryl ether oxygen of 4a–4f or the aniline nitrogen of 10a–10f could be detected in the structures docked into the cryo-EM structure of the channel.
Compound | 4a | 4b | 4c | 4d | 4e | 4f |
---|---|---|---|---|---|---|
CLint (μL min−1 mg−1 protein) | 34 | 105 | 83 | 132 | 97 | 239 |
Cpd CLint/diazepam CLint | 1.8 | 2.0 | 4.4 | 6.9 | 5.1 | 12.5 |
Again, for the first time, this class of compound was tested for metabolic stability in an in vitro liver microsome assay. Hydroxylation and demethylation were found to be the main metabolic routes, with the rate of degradation of the methylamines 4a and 4b comparing favourably with the positive control diazepam, a drug that is considered long acting. Finally, the likelihood of the dimethylamine 4b to enter the CNS, as judged by its calculated MPO score, appears to be high, yielding a value well within the range of many CNS-active drugs and superior to the neuropathic pain medications gabapentin and pregabalin, and the related open chain analogue 16.
In summary, the replacement of the acyl link in previously reported phenoxazine-based CaV2.2 inhibitors has led to compounds with improved metabolic stability and affinity for the channel that is equivalent to the best reported for this class of compound. One of the most active compounds (4b) is also more likely to penetrate the blood brain barrier, based on its CNS MPO score. In addition, molecular modelling using a recently reported cryo-EM structure of the channel has been employed to predict where in the channel this class of inhibitor binds and how they exert their inhibitory effect. Based on our previous findings, future optimisation of the lead structure will involve exploring substitution of the aromatic rings. Additionally, future studies will investigate the state-dependency of the most active compounds using electrophysiology assays, and will test the most potent lead compound for blood–brain barrier penetration.
Thin-layer chromatography (TLC) was performed using TLC Silica Gel 60 F254 and visualised under UV lamp or through the use of an appropriate stain such as potassium permanganate or ninhydrin. Melting points were recorded in an ISG melting point apparatus.
Proton nuclear magnetic resonance (1H NMR) and Fluorine nuclear magnetic resonance (19F NMR) spectra were recorded on a Bruker AV400 or AV600 as specified. The resonance shifts were assigned based on the chemical shift (δ – measured in ppm), multiplicity (s – singlet, d – doublet, t – triplet, q – quartet, etc.), number of protons, observed coupling constant (J – measured in Hz). Carbon-13 nuclear magnetic resonance (13C NMR) spectra were recorded on Bruker AV400 or AV600 at 100 or 150 MHz respectively. All chemical shifts referenced to either TMS or the residual solvent peak unless otherwise stated.
High-resolution mass spectrometry (APCI, ESI) was conducted on a Thermo Scientific QExactive FT-MS. Positive ion EI mass spectra were performed using a Thermo Scientific DFS mass spectrometer using an ionisation energy of 70 eV. Accurate mass measurements were obtained with a resolution of 5000–10000 using PFK (perfluorokerosene) as the reference compound.
High Performance Liquid Chromatography (HPLC) methods (Methods 1–5) are detailed in the Supplementary Information.
1H NMR (CDCl3, 400 MHz) δ (ppm) = 7.69 (dd, J = 7.8, 1.8 Hz, 2H), 7.26–7.12 (m, 4H), 7.07–6.98 (m, 2H), 6.84 (dd, J = 7.9, 1.6 Hz, 2H), 6.76–6.68 (m, 2H), 4.12 (t, J = 5.9 Hz, 2H), 3.74 (t, J = 6.2 Hz, 2H), 2.25 (p, J = 6.1 Hz, 2H).
13C NMR (CDCl3, 100 MHz) δ(ppm) = 162.70, 151.20, 129.93, 128.32, 128.16, 127.43, 126.45, 123.78, 116.28, 114.10, 64.67, 41.14, 31.98.
1H NMR (MeOD, 600 MHz) δ (ppm) = 7.62 (dd, J = 8.0, 1.6 Hz, 2H), 7.28 (td, J = 7.8, 1.6 Hz, 2H), 7.21 (td, J = 7.7, 1.4 Hz, 2H), 7.01–6.95 (m, 2H), 6.86 (td, J = 8.0, 1.8 Hz, 4H), 4.13 (t, J = 5.7 Hz, 2H), 3.21 (t, J = 7.3 Hz, 2H), 2.75 (s, 3H), 2.22–2.14 (m, 2H).
13C NMR (MeOD, 150 MHz) δ (ppm) = 162.75, 151.19, 129.68, 128.39, 127.72, 127.41, 126.33, 123.52, 116.01, 114.00, 65.24, 46.67, 32.45, 25.53.
HRMS (APCI): m/z calculated for [M + H]+: 411.1373, found 411.1374.
1H NMR (MeOD, 600 MHz) δ (ppm) = 7.62 (dd, J = 8.0, 1.6 Hz, 2H), 7.28 (td, J = 7.8, 1.6 Hz, 2H), 7.21 (td, J = 7.7, 1.4 Hz, 2H), 7.01–6.95 (m, 2H), 6.89–6.83 (m, 4H), 4.13 (t, J = 5.8 Hz, 2H), 3.36–3.33 (m, 2H), 2.95 (s, 6H), 2.27–2.19 (m, 2H).
13C NMR (MeOD, 150 MHz) δ (ppm) = 162.73, 151.20, 129.69, 128.39, 127.73, 127.41, 126.33, 123.52, 116.02, 113.99, 65.00, 55.10, 42.20, 24.08.
HRMS (APCI): m/z calculated for [M + H]+: 425.1530, found 425.1526.
1H NMR (MeOD, 600 MHz) δ (ppm) = 7.61 (dd, J = 8.0, 1.6 Hz, 2H), 7.28 (td, J = 7.8, 1.7 Hz, 2H), 7.20 (td, J = 7.7, 1.4 Hz, 2H), 7.00–6.95 (m, 2H), 6.87–6.81 (m, 4H), 4.11 (t, J = 5.8 Hz, 2H), 3.63–3.56 (m, 2H), 3.32–3.26 (m, 2H), 2.97 (td, J = 12.6, 3.0 Hz, 2H), 2.28–2.20 (m, 2H), 2.02–1.95 (m, 2H), 1.91–1.73 (m, 3H), 1.60–1.49 (m, 1H).
13C NMR (MeOD, 150 MHz) δ (ppm) = 162.76, 151.19, 129.70, 128.41, 127.71, 127.34, 126.31, 123.52, 116.03, 113.96, 65.06, 54.18, 53.05, 23.58, 22.90, 21.27.
HRMS (APCI): m/z calculated for [M + H]+: 451.1686, found 451.1685.
1H NMR (MeOD, 600 MHz) δ (ppm) = 8.99 (s, 1H), 7.69 (t, J = 1.8 Hz, 1H), 7.62 (dd, J = 8.0, 1.6 Hz, 2H), 7.59 (t, J = 1.7 Hz, 1H), 7.28 (td, J = 7.7, 1.8 Hz, 2H), 7.21 (td, J = 7.5, 1.3 Hz, 2H), 7.00–6.94 (m, 2H), 6.86 (dd, J = 8.1, 1.4 Hz, 2H), 6.83–6.77 (m, 2H), 4.48 (t, J = 7.0 Hz, 2H), 4.10 (t, J = 5.7 Hz, 2H), 2.40 (p, J = 6.2 Hz, 2H).
13C NMR (MeOD, 150 MHz) δ (ppm) = 162.70, 151.21, 135.23, 129.70, 128.39, 127.73, 127.37, 126.34, 123.52, 122.05, 119.84, 116.01, 113.90, 64.93, 46.53, 29.11.
HRMS (APCI): m/z calculated for [M + H]+: 448.1326, found 448.1327.
1H NMR (MeOD, 600 MHz) δ (ppm) = 7.61 (dd, J = 8.0, 1.6 Hz, 2H), 7.28 (td, J = 7.8, 1.6 Hz, 2H), 7.20 (td, J = 7.7, 1.4 Hz, 2H), 7.00–6.95 (m, 2H), 6.88–6.81 (m, 4H), 4.12 (t, J = 5.8 Hz, 2H), 3.83–3.55 (m, 2H), 3.43–3.37 (m, 2H), 3.13 (s, 2H), 2.30–1.98 (m, 6H).
13C NMR (MeOD, 150 MHz) δ (ppm) = 162.76, 151.20, 129.70, 128.40, 127.72, 127.36, 126.32, 123.52, 116.02, 113.98, 64.98, 53.96, 52.17, 48.19, 25.43, 22.57.
HRMS (APCI): m/z calculated for [M + H]+: 465.1843, found 465.1845.
1H NMR (MeOD, 600 MHz) δ (ppm) = 7.62 (dd, J = 8.0, 1.6 Hz, 2H), 7.28 (td, J = 7.9, 1.6 Hz, 2H), 7.21 (td, J = 7.7, 1.4 Hz, 2H), 7.02–6.94 (m, 2H), 6.89–6.83 (m, 4H), 4.17–4.04 (m, 4H), 3.83–3.74 (m, 2H), 3.60–3.52 (m, 2H), 3.41–3.32 (m, 2H), 3.25–3.15 (m, 2H), 2.30–2.22 (m, 2H).
13C NMR (MeOD, 150 MHz) δ (ppm) = 162.71, 151.20, 129.72, 128.39, 127.73, 127.47, 126.34, 123.53, 116.00, 113.96, 64.93, 63.69, 54.46, 51.92, 23.27.
HRMS (APCI): m/z calculated for [M + H]+: 467.1635, found 467.1636.
MP: 170–172 °C.
1H NMR (CDCl3, 400 MHz) δ (ppm) = 8.15–8.07 (m, 2H), 7.70 (dd, J = 7.8, 1.8 Hz, 2H), 7.33–7.18 (m, 6H), 6.86 (dd, J = 7.9, 1.6 Hz, 2H).
13C NMR (CDCl3, 100 MHz) δ (ppm) = 151.09, 141.00 (HMBC), 129.02, 128.98, 127.96, 125.67, 124.24, 123.56, 116.65.
MP: 110–112 °C.
1H NMR (CDCl3, 400 MHz) δ (ppm) = 7.67 (dd, J = 7.8, 1.8 Hz, 2H), 7.24–7.12 (m, 5H), 6.90–6.79 (m, 4H), 6.49 (d, J = 8.5 Hz, 2H).
13C NMR (CDCl3, 100 MHz) δ 151.24, 150.93, 129.87, 128.22, 128.14, 126.65, 123.95, 123.66, 116.19, 113.58.
1H NMR (CDCl3, 400 MHz) δ (ppm) = 7.58 (dd, J = 7.8, 1.8 Hz, 2H), 7.41–7.35 (m, 2H), 7.16–7.05 (m, 5H), 6.98–6.91 (m, 2H), 6.74 (dd, J = 7.9, 1.6 Hz, 2H), 3.78 (t, J = 6.3 Hz, 2H), 2.76 (t, J = 6.3 Hz, 2H).
13C NMR (CDCl3, 100 MHz) δ (ppm) = 168.01, 151.17, 142.28, 130.48, 129.11, 128.50, 128.05, 126.22, 123.87, 118.64, 116.43, 40.52, 39.41.
1H NMR (CDCl3, 400 MHz) δ (ppm) = 8.55 (s, 1H), 7.58 (dd, J = 7.9, 1.8 Hz, 2H), 7.15–7.00 (m, 4H), 6.80–6.68 (m, 4H), 6.30–6.16 (m, 2H), 3.55 (t, J = 6.4 Hz, 2H), 3.25 (t, J = 6.7 Hz, 2H), 2.02–1.87 (m, 2H).
13C NMR (CDCl3, 100 MHz) δ (ppm) = 151.88, 151.25, 147.56, 139.00, 129.86, 128.24, 128.11, 126.72, 125.30, 123.64, 122.49, 116.16, 111.14, 42.25, 40.38, 31.54.
1H NMR (MeOD, 400 MHz) δ (ppm) = 7.49 (dd, J = 7.9, 1.6 Hz, 2H), 7.17 (td, J = 7.8, 1.6 Hz, 2H), 7.08 (td, J = 7.7, 1.5 Hz, 2H), 6.77 (dd, J = 8.1, 1.4 Hz, 2H), 6.70–6.61 (m, 2H), 6.37–6.29 (m, 2H), 3.13 (td, J = 8.2, 7.5, 4.2 Hz, 4H), 2.62 (s, 3H), 1.97–1.85 (m, 2H).
13C NMR (MeOD, 100 MHz) δ (ppm) = 152.94 (HMBC), 151.29, 129.48, 128.14, 127.78, 126.62, 123.30, 120.93, 115.93, 110.51, 55.55, 42.13, 39.26, 23.69.
HRMS (APCI): m/z calculated for [M + H]+: 410.1533, found 410.1533.
1H NMR (MeOD, 400 MHz) δ 7.59 (dd, J = 7.9, 1.6 Hz, 2H), 7.22 (dtd, J = 32.4, 7.6, 1.6 Hz, 4H), 6.89–6.72 (m, 4H), 6.49–6.34 (m, 2H), 3.26–3.17 (m, 4H), 2.90 (s, 6H), 2.06–1.93 (m, 2H).
13C NMR (MeOD, 100 MHz) δ 152.97 (HMBC), 151.28, 129.49, 128.11, 127.80, 126.64, 123.30, 121.03, 115.90, 110.48, 55.56, 42.12, 39.24, 23.71.
HRMS (APCI): m/z calculated for [M + H]+: 424.1689, found 424.1690.
1H NMR (MeOD, 400 MHz) δ (ppm) = 7.59 (dd, J = 7.9, 1.7 Hz, 2H), 7.31–7.13 (m, 4H), 6.86 (dd, J = 8.1, 1.5 Hz, 2H), 6.78–6.71 (m, 2H), 6.46–6.37 (m, 2H), 3.71–3.62 (m, 2H), 3.30–3.20 (m, 6H), 3.14–3.03 (m, 2H), 2.23–1.95 (m, 6H).
13C NMR (MeOD, 100 MHz) δ (ppm) = 152.92 (HMBC), 151.29, 129.49, 128.10, 127.79, 126.66, 123.29, 121.00 (HMBC), 115.90, 110.48, 53.91, 52.73, 39.33, 25.12, 22.57.
HRMS (APCI): m/z calculated for [M + H]+: 450.1846, found 450.1843.
1H NMR (MeOD, 600 MHz) δ (ppm) = 8.77 (s, 1H), 7.62–7.57 (m, 3H), 7.51 (s, 1H), 7.26 (td, J = 7.7, 1.7 Hz, 2H), 7.18 (td, J = 7.7, 1.5 Hz, 2H), 6.86 (dd, J = 8.1, 1.4 Hz, 2H), 6.78–6.72 (m, 2H), 6.41–6.35 (m, 2H), 4.34 (t, J = 7.2 Hz, 2H), 3.17 (t, J = 6.7 Hz, 2H), 2.18 (p, J = 6.9 Hz, 2H).
13C NMR (MeOD, 100 MHz) δ 153.00, 151.29, 135.07, 129.46, 128.14, 127.78, 126.62, 123.30, 121.87, 120.22, 115.93, 110.46, 104.98, 46.88, 39.06, 28.87.
HRMS (APCI): m/z calculated for [M + H]+: 447.1485, found 447.1485.
1H NMR (CD3CN, 600 MHz) δ 7.47 (dd, J = 8.0, 1.6 Hz, 2H), 7.17 (td, J = 7.8, 1.6 Hz, 2H), 7.08 (td, J = 7.7, 1.4 Hz, 2H), 6.77 (dd, J = 8.1, 1.4 Hz, 2H), 6.62 (d, J = 8.9 Hz, 2H), 6.31–6.24 (m, 2H), 3.33 (d, J = 12.2 Hz, 2H), 3.02 (t, J = 6.6 Hz, 2H), 2.98–2.90 (m, 2H), 2.66 (d, J = 14.1 Hz, 2H), 1.87 (dd, J = 9.9, 4.9 Hz, 2H), 1.79–1.58 (m, 6H).
13C NMR (CD3CN, 150 MHz) δ 153.66, 151.87, 130.35, 129.28, 128.66, 127.32, 124.46, 121.63, 116.97, 111.55, 55.22, 53.70, 40.40, 23.61, 23.37, 22.07.
HRMS (ESI): m/z calculated for [M + H]+: 464.2002, found: 464.2004.
1H NMR (MeOD, 600 MHz) δ (ppm) = 7.59 (dd, J = 8.0, 1.6 Hz, 2H), 7.25 (td, J = 7.7, 1.6 Hz, 2H), 7.18 (td, J = 7.7, 1.4 Hz, 2H), 6.86 (dd, J = 8.1, 1.4 Hz, 2H), 6.79–6.73 (m, 2H), 6.45–6.39 (m, 2H), 4.12–4.02 (m, 2H), 3.81–3.71 (m, 2H), 3.50 (d, J = 12.5 Hz, 2H), 3.28–3.21 (m, 4H), 3.19–3.09 (m, 2H), 2.07–1.98 (m, 2H).
13C NMR (MeOD, 150 MHz) δ (ppm) = 152.89, 151.28, 129.49, 128.10, 127.78, 126.64, 123.28, 121.06, 115.91, 110.48, 63.64, 55.01, 51.86, 39.30, 22.89.
HRMS (APCI): m/z calculated for [M + H]+: 466.1795, found 466.1794.
1H NMR (CD3CN, 600 MHz) δ 7.53 (dd, J = 8.0, 1.6 Hz, 2H), 7.21 (td, J = 7.7, 1.6 Hz, 2H), 7.13 (td, J = 7.7, 1.4 Hz, 2H), 6.81 (dd, J = 8.1, 1.4 Hz, 2H), 6.74–6.69 (m, 2H), 6.47–6.41 (m, 2H), 3.34 (t, J = 7.4 Hz, 2H), 2.97–2.89 (m, 2H), 2.86 (s, 3H), 2.67 (s, 6H), 1.88–1.83 (m, 2H + CD3CN).
13C NMR (CD3CN, 150 MHz,) δ 153.27, 151.86, 130.16, 129.25, 128.65, 127.34, 124.43, 121.18, 116.98, 111.16, 55.40, 49.31, 43.06, 38.24, 22.28.
HRMS (ESI): m/z calculated for [M + H]+: 438.1846, found: 438.1849.
1H NMR (MeOD, 600 MHz) δ (ppm) = 7.59 (dd, J = 8.0, 1.6 Hz, 2H), 7.25 (td, J = 7.9, 1.4 Hz, 2H), 7.18 (td, J = 7.6, 1.4 Hz, 2H), 6.86 (dd, J = 8.1, 1.4 Hz, 2H), 6.79–6.73 (m, 2H), 6.49–6.43 (m, 2H), 3.67–3.61 (m, 1H), 3.48–3.41 (m, 2H), 3.14 (td, J = 12.6, 3.1 Hz, 2H), 2.20 (dd, J = 14.6, 3.8 Hz, 2H), 1.67 (dtd, J = 14.2, 10.6, 3.9 Hz, 2H).
13C NMR (MeOD, 150 MHz) δ (ppm) = 151.76, 151.31, 129.54, 128.09, 127.80, 126.66, 123.28, 121.11, 115.90, 110.81, 46.20, 42.67, 28.30.
HRMS (APCI): m/z calculated for [M + H]+: 421.1455, found 421.1456.
1H NMR (600 MHz, Methanol-d4) δ 7.61 (dd, J = 7.9, 1.6 Hz, 2H), 7.31–7.25 (m, 2H), 7.20 (td, J = 7.7, 1.4 Hz, 2H), 6.97–6.92 (m, 2H), 6.88 (dd, J = 8.1, 1.4 Hz, 2H), 6.84–6.79 (m, 2H), 4.60 (s, 3H), 4.08 (t, J = 6.3 Hz, 2H), 3.56 (t, J = 6.2 Hz, 2H), 2.03 (p, J = 6.2 Hz, 2H).
13C NMR (150 MHz, MeOD) δ 163.44, 151.25, 129.64, 128.37, 127.70, 126.63, 126.36, 123.43, 116.05, 113.91, 68.54, 65.04, 57.48, 28.90.
HRMS (ESI): m/z calculated for [M + H]+: 412.1213, found: 412.1211.
For each compound of interest, the experiment was repeated in triplicate alongside one positive control experiment with diltiazem. The amount of compound of interest remaining at the various time points was determined from the peak area ratio of compound to diazepam. The data was then plotted and, where appropriate, fitted to a one-phase decay model using GraphPad Prism 8.0.2. Representative chromatograms are included in ESI.†
For each compound of interest, the experiment was repeated in triplicate alongside one positive control experiment with diazepam. For each sample, the chromatogram of the ion corresponding to the compound of interested was extracted. A calibration curve was made in order to determine the amount of compound of interest remaining at each time point. The data was then plotted and fitted to a one-phase decay model using GraphPad Prism 8.0.2. Representative chromatograms are attached in ESI.†
• Docking site 1: P2III and P2IV segments.
• Docking site 2: S5III, S6III and S6IV segments.
• Docking site 3: lower parts of the S6I, S6II, S6III and S6IV segments.
The structures of the compounds of interest were then imported and their possible ionization states at pH = 7.4 ± 2.0 were generated using the LigPrep utility. Rigid docking of the compounds of interest was performed with the docking grid corresponding to sites 1, 2 and 3 using the Glide Ligand Docking utility. Docking scores were exported and plotted in GraphPad 8.0.2 for analysis. Fig. 3 and 5 were generated using the Visual Molecular Dynamics (VMD) 1.9.3 package. VMD was developed by the Theoretical and Computational Biophysics Group in the Beckman Institute for Advanced Science and Technology at the University of Illinois at Urbana-Champaign.26
Footnotes |
† Electronic supplementary information (ESI) available: Synthesis of 2, NMR spectra, rat plasma stability and liver microsomal stability studies. See DOI: https://doi.org/10.1039/d4md00336e |
‡ Current address: Pharmacy Discipline, Life Science School, Khulna University, Khulna, 9208, Bangladesh. |
§ The abbreviations used to identify the various segments and loops in the CaV2.2 protein structure are defined in a previous publication.5 |
This journal is © The Royal Society of Chemistry 2024 |